May 19, 2008 (CIDRAP News) – Indonesia’s recent announcement that it would immediately begin sharing H5N1 avian influenza genetic sequences with a new public database is being hailed by experts as a promising development, though there is a concern that having actual virus isolates would be better.Indonesia’s decision, announced by Health Minister Siti Fadilah Supari, was detailed in a May 15 report from the Associated Press (AP).In early 2007 Indonesia stopped sharing H5N1 virus samples with the World Health Organization (WHO) to protest what it perceived as a lack of access to costly pandemic vaccines that companies in developed countries produce from the shared samples. The government has shared only a few samples with WHO labs since then.Though Indonesia’s embargo has drawn support from some other developing countries and nongovernmental organizations, the country was widely criticized by global health officials and researchers, who have said sample sharing is crucial for tracking the evolution of the virus and developing treatments and vaccines.”We have always promoted the sharing of influenza data, all we ask for is that it be done in a fair, transparent, and equitable manner,” Supari said of Indonesia’s decision to contribute sequence data to the new database, known as the Global Initiative on Sharing Avian Influenza Data (GISAID), according to the AP report.A WHO working group has met several times to resolve the virus-sharing dispute, but has made little progress. The issue is expected to surface at the annual World Health Assembly, which started today in Geneva. However, the working group’s next formal meeting is scheduled for November.Benefits, limitations of sequence dataTwo researchers who work with H5N1 viruses say they are pleased that Indonesia, which leads the world in human H5N1 cases and deaths, will share the genetic sequences from their virus samples. However, their opinions varied on how useful the genetic sequences will be without the actual H5N1 virus isolates, which are used to make seed strains for vaccines.Richard Webby, PhD, a virologist at St Jude Children’s Research Hospital in Memphis, Tenn., told CIDRAP News that the sequences would allow researchers to track virus evolution.”It is absolutely a step in the right direction, and it allows everyone to see how the Indonesian viruses are evolving genetically,” Webby said. “Unfortunately, however, our ability to accurately predict antigenic and biologic properties from sequence data alone is embarrassingly poor. So, no, it [providing genetic sequence data] is not as good as sharing viruses.”Webby added that the most important aspect scientists can determine from a viral isolate that they can’t learn from a sequence is antigenicity—how well a virus will cross-react with antibodies generated against other strains. “Antigenic relatedness, not genetic relatedness, is key to vaccine strain selection,” he said.Also, sequence data alone can’t predict the transmission and pathogenicity changes that researchers depend on to make risk assessments, Webby said.Adolfo Garcia-Sastre, PhD, a virologist at Mount Sinai School of Medicine in New York City, also welcomed the news about Indonesia sharing its viral sequences and voiced a more optimistic view on their usefulness.”Sequences are very important to understand antigenicity, and even if no viruses are shared, provide the basis to make reagents to experimentally test antigenicity and pathogenicity,” he told CIDRAP News. Garcia-Sastre is also principal investigator for the Center for Research on Influenza Pathogenesis, one of six National Institute for Allergy and Infectious Diseases Centers of Excellence for Influenza Research and Surveillance.GISAID launches data-sharing platformThe idea for the GISAID database was generated by a group of 70 scientists and health officials who signed a letter in the August 31, 2006, issue of Nature proposing the formation of a new consortium to promote greater sharing of H5N1 genetic sequences.Aside from concerns about potential social inequities, virus-sharing has been a flashpoint for other controversies, including intellectual property rights and published credits for virus sources in scientific papers.Supari had earlier signaled Indonesia’s support for the GISAID database when she announced its initial launch in March 2007, according to a Mar 28, 2007, GISAID press release. Her support for the GISAID database followed a technical meeting on the virus-sharing issue that was attended by health ministers of countries that have been hit by the H5N1 virus, GISAID’s statement said.An official with GISAID, who asked not to be named, told CIDRAP News that the database’s platform for sharing H5N1 genetic sequences went live on May 15. The official confirmed that Indonesia has committed to sharing its virus data and is currently uploading its sequences into the GISAID EpiFlu database. China, Russia, and other nations are also in the process of submitting sequences, the GISAID source said.”This global health research community will find that the GISAID platform provides a high standard of data and analysis tools that uniquely promotes responsible sharing of information,” Supari said in the 2007 press release.GISAID said the public can freely access the database, which includes both human and animal H5N1 sequences, after they register and agree to share and credit the use of others’ data, analyze findings jointly, publish results collaboratively, and refrain from pressing intellectual property rights issues that relate to diagnostic, drug, and vaccine developments.When the plan to form GISAID was announced in 2006, one of the global health officials who signed the Nature letter was Dr. Nancy Cox, head of the Influenza Division at the US Centers for Disease Control and Prevention (CDC). Cox had told CIDRAP News that the GISAID database would be very useful because it would be linked with clinical and epidemiological data.The efforts of Peter Bogner, GISAID director, were instrumental in garnering the support of Supari and other officials, the AP reported. Bogner is a former broadcast executive who became involved in virus-sharing issues after attending a World Economic Forum in Switzerland 2 years ago, the report said.See also:Aug 25, 2006, CIDRAP News story “Scientists launch effort to share avian flu data”GISAID Web sitehttp://www.gisaid.org/WHO World Health Assembly agenda and proceedings
After three seasons on loan at Atletico Madrid, the 22-year-old Belgium goalkeeper has returned to Stamford Bridge and taken the place Cech has occupied for a decade. Courtois has two years remaining on the contract he signed when moving from Genk in July 2011, with an extension close. “It’s not yet signed,” Courtois told Sky Sports. “I am here with the national team so it is difficult, but when I am back at Chelsea I will probably sign the new contract.” Courtois started the first three Barclays Premier League games of the season ahead of Cech. It is a situation reminiscent of when Cech was installed as number one ahead of the established Carlo Cudicini after his signing from Rennes in June 2004. Mourinho’s decision led to suggestions Cech would leave, but the Czech Republic goalkeeper remains after Monday’s closure of the summer transfer window despite reported interest from Paris St Germain and Real Madrid. Courtois added: “We don’t talk about the situation, but of course I know he has played 10 years at Chelsea and that now I am playing and for him it’s not the nicest situation. But that is the decision of the board and the trainer. “He is working hard in training to be ready when I cannot play or I am maybe not playing well. We work well together. “Of course as a professional and a winner you always want to play every game, so we will see what the decision is of the coach. “But of course I am a professional player and I want to play every game that is possible.” Press Association Thibaut Courtois has revealed he is close to signing a new contract with Chelsea after ousting Petr Cech as Jose Mourinho’s first-choice goalkeeper.